We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Patient Preference Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00576342
Recruitment Status : Completed
First Posted : December 19, 2007
Last Update Posted : July 11, 2014
Information provided by (Responsible Party):
Alcon Research

Brief Summary:
In this randomized crossover study, patients will receive a single drop of two test articles and assess comfort.

Condition or disease Intervention/treatment Phase
Glaucoma Ocular Hypertension Drug: AL-3862+timolol ophthalmic suspension Drug: Dorzolamide+timolol ophthalmic solution Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 129 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Single Dose Patient Preference Study Comparison in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study Start Date : December 2007
Primary Completion Date : January 2008
Study Completion Date : January 2008

Arm Intervention/treatment
AL-3862+timolol, then COSOPT
AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, followed by dorzolamide+timolol ophthalmic solution,1 drop in both eyes, 1 day later.
Drug: AL-3862+timolol ophthalmic suspension Drug: Dorzolamide+timolol ophthalmic solution
Other Name: COSOPT
COSOPT, then AL-3862+timolol
Dorzolamide+timolol ophthalmic solution, 1 drop in both eyes, followed by AL-3862+timolol ophthalmic suspension, 1 drop in both eyes, 1 day later.
Drug: AL-3862+timolol ophthalmic suspension Drug: Dorzolamide+timolol ophthalmic solution
Other Name: COSOPT

Primary Outcome Measures :
  1. Percentage of patients with a stated preference for either study medication [ Time Frame: Day 2 ]

Secondary Outcome Measures :
  1. Mean ocular discomfort score [ Time Frame: Day 1, 1 minute after drop instillation ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Sign informed consent;
  • Diagnosis of glaucoma or ocular hypertension;
  • On a stable regimen of any intraocular pressure (IOP) lowering medication (mono-therapy);
  • IOP for which, in the opinion of the investigator, participation in the study does not present a risk to ocular health;
  • Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

  • Best corrected visual acuity worse than 0.60 logMAR (20/80 Snellen) in either eye;
  • Pregnant, nursing, or not using highly effective birth control methods;
  • Use of oral or topical corticosteroids within 30 days of the Screening Visit and during the course of the study;
  • History of bronchial asthma or severe chronic obstructive pulmonary disease;
  • Other protocol-defined exclusion criteria may apply.

Responsible Party: Alcon Research
ClinicalTrials.gov Identifier: NCT00576342     History of Changes
Other Study ID Numbers: C-07-47
First Posted: December 19, 2007    Key Record Dates
Last Update Posted: July 11, 2014
Last Verified: July 2014

Additional relevant MeSH terms:
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases
Pharmaceutical Solutions
Ophthalmic Solutions
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Carbonic Anhydrase Inhibitors
Enzyme Inhibitors